Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 11/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536777 | 0.97 | DGAT1 (0.72) | DGAT1RAB9ANPC1GFERMT-CO2 | |
| SCHEMBL3543985 | 0.91 | DGAT1 (0.63) | DGAT1RAB9ANPC1MT-CO2MAPT | |
| SCHEMBL3547422 | 0.89 | DGAT1 (0.75) | DGAT1MAPT | |
| SCHEMBL3546009 | 0.89 | DGAT1 (0.75) | DGAT1RAB9ANPC1MAPTPKM | |
| SCHEMBL3542098 | 0.88 | DGAT1 (0.65) | DGAT1 | |
| SCHEMBL3543051 | 0.87 | DGAT1 (0.80) | DGAT1RAB9ANPC1MT-CO2LMNA | |
| SCHEMBL3547403 | 0.87 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL3547530 | 0.86 | DGAT1 (0.77) | DGAT1RAB9ANPC1LMNAMAPT | |
| SCHEMBL3543610 | 0.85 | DGAT1 (0.86) | DGAT1RAB9ANPC1 | |
| SCHEMBL3544698 | 0.85 | DGAT1 (0.71) | DGAT1RAB9ANPC1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | DGAT1 1/4885RAB9A 2923/4885NPC1 423/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | DGAT1 1/4885RAB9A 2977/4885NPC1 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.